Bristol-Myers Squibb Company
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher S. Boerner
- Full Time Employees
- 32,500
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Route 206 & Province Line Road Princeton NJ United States 08543
- IPO Date
- Jul 5, 1929
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.
Company News
48,234 Shares in Bristol Myers Squibb Company $BMY Acquired by Associated Banc Corp
3 of the Best Dividend Stocks to Own
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Bristol Myers Squibb Q3 Earnings Call Highlights
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates
Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
3 Magnificent Dividend Stocks for Risk-Averse Investors
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
8,656 Bristol Myers Squibb Company $BMY Shares Sold by Evergreen Capital Management LLC
Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters